Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis.
Antonio TonuttiFrancesca MottaNatasa IsailovicAngela CeribelliRita RagusaEmanuele NappiStefanos BonovasCarlo Francesco SelmiMaria De SantisPublished in: RMD open (2024)
Cancer surveillance should be particularly careful in patients with diffuse SSc, increased age at disease onset and without classical SSc-related autoantibodies.